 |
|
First diagnostic indicator for Amytrophic Lateral Sclerosis (ALS) identified
February 23, 2006Mount Sinai School of Medicine researchers have identified three proteins that may be first tools for confirming diagnosis of ALS
Claire Collier went to see her doctor shortly after she started experiencing cramping and other symptoms. This started a series of referrals and seemingly endless stream of tests. Finally, nine months later after test after test had come back negative, she received the diagnosis of ALS. Only then could she begin to receive the treatment needed to treat her symptoms.
There was not then and is not now a simple test that can tell a patient whether or not they have ALS. But a study published in this month's issue of Neurology may change that.
Researchers from Mount Sinai School of Medicine identified three proteins that are found in significantly lower concentration in the cerebral spinal fluid of patients with ALS than in healthy individuals. These are the first biomarkers for this disease.
"ALS is a very difficult disease to diagnose. To date, there is no one test or procedure to ultimately establish the diagnosis of ALS. It is through a clinical examination and series of diagnostic tests, often ruling out other diseases," website of the ALS Association.
Giulio Pasinetti, MD, PhD, Professor of Psychiatry, Neuroscience, and Geriatrics and Adult Development, Mount Sinai School of Medicine and colleagues compared cerebral spinal fluid from patients diagnosed with ALS, patients with other neurological disorders, and healthy individuals. They found that fluid from patients with ALS had significantly lower concentrations of three proteins than either of the other groups. Evaluating the levels of these three proteins proved 95% accurate for diagnosing ALS.
The researchers found that the changes in concentration of these proteins were evident within 1.5 years of onset of symptoms. With current methods, the average time from onset of symptoms to diagnosis is two years. Testing for these protein concentrations may provide a means of early diagnosis, allowing patients to receive relief from symptoms years earlier.
"For the first time we have the possibility of developing a test that can definitively say whether or not a patient has ALS," said Dr. Pasinetti. "Such a test would eliminate the need for patients to undergo months of diagnostic evaluation and remove the uncertainty that currently lingers with physicians and patients even after a diagnosis is made."
The Mount Sinai Hospital / Mount Sinai School of Medicine
Researchers from Mount Sinai School of Medicine identified three proteins that are found in significantly lower concentration in the cerebral spinal fluid of patients with ALS than in healthy individuals. These are the first biomarkers for this disease.
"ALS is a very difficult disease to diagnose. To date, there is no one test or procedure to ultimately establish the diagnosis of ALS. It is through a clinical examination and series of diagnostic tests, often ruling out other diseases," website of the ALS Association.
Giulio Pasinetti, MD, PhD, Professor of Psychiatry, Neuroscience, and Geriatrics and Adult Development, Mount Sinai School of Medicine and colleagues compared cerebral spinal fluid from patients diagnosed with ALS, patients with other neurological disorders, and healthy individuals. They found that fluid from patients with ALS had significantly lower concentrations of three proteins than either of the other groups. Evaluating the levels of these three proteins proved 95% accurate for diagnosing ALS.
The researchers found that the changes in concentration of these proteins were evident within 1.5 years of onset of symptoms. With current methods, the average time from onset of symptoms to diagnosis is two years. Testing for these protein concentrations may provide a means of early diagnosis, allowing patients to receive relief from symptoms years earlier.
"For the first time we have the possibility of developing a test that can definitively say whether or not a patient has ALS," said Dr. Pasinetti. "Such a test would eliminate the need for patients to undergo months of diagnostic evaluation and remove the uncertainty that currently lingers with physicians and patients even after a diagnosis is made."
The Mount Sinai Hospital / Mount Sinai School of Medicine
ALS Current Events and ALS News RSSNew class of brain-protecting drugs emerging
Researchers have identified a compound that mimics one of the brain's own growth factors and can protect brain cells against damage in several animal models of neurological disease.
Gladstone scientists identify role of key protein in ALS and frontotemporal dementia
Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.
New ALS drug slips through telling 'phase II' clinical trials
A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial-an early, small-scale test to show if the drug works and continues to be safe.
Heavy metal paradox could point toward new therapy for Lou Gehrig's disease
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
Research sheds light on workings of anti-cancer drug
The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.
New understanding about mechanism for cell death after stroke leads to possible therapy
Scientists at the Brain Research Centre, a partnership of the University of British Columbia Faculty of Medicine and Vancouver Coastal Health Research Institute, have uncovered new information about the mechanism by which brain cells die following a stroke, as well as a possible way to mitigate that damage.
Schizophrenia gene's role may be broader, more potent, than thought
UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia.
Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.
Dysfunctional protein dynamics behind neurological disease?
Researchers at Lund University, Sweden, have taken a snapshot of proteins changing shape, sticking together and creating structures that are believed to trigger deadly processes in the nervous system.
New guidelines identify best treatments to help ALS patients live longer, easier
New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.
More ALS Current Events and ALS News Articles
 |
I Choose to Live: A Journey Through Life with ALS by William Sinton (Author) |
 |
I Remember Running: The Year I Got Everything I Ever Wanted-and ALS by Darcy Wakefield (Author) A little over a year ago, Darcy Wakefield was a single, 33-year-old athletic, workaholic English professor, a vegetarian who had never had a serious health problem or injury. Then she was diagnosed with ALS, and her world turned upside down. I Remember Running is Darcy's story of change and loss and challenges during her first year with ALS, as she struggles to make sense of her diagnosis and redefine herself in the face of this terminal illness. With unflagging courage, wit, and eloquence, Darcy shares what she calls her "fast-forward" life, a life in which she applies for disability, leaves her job, and plans her own funeral as well as meets and moves in with her true love, buys a house, and gives birth to her first child in less time than it takes most of us to accomplish even one of... |
 |
If They Could Only Hear Me: A collection of personal stories about ALS and the families that have been affected. by Ed Rice (Editor) This collection of personal stories was assembled to help bring more awareness to an insidious disease called amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s disease. |
 |
So Much So Fast Starring: Stephen Heywood, Jamie Heywood Directed By: Steven Ascher;Jeanne Jordan What would you do if you were 29 and found you may only have a few years to live? So Much So Fast is about the remarkable events set in motion when Stephen Heywood discovers he has ALS (Lou Gehrig's disease) and his brother Jamie becomes obsessed with finding a cure. |
 |
Amyotrophic Lateral Sclerosis: A Guide for Patients and Families by M.D. Hiroshi Mitsumoto (Editor) This important book covers every aspect of living with ALS, from clinical features of the disease to an overview of symptom management to understanding its diagnosis. Major sections deal with overseeing medical care and rehabilitation, living with ALS, the disease’s advanced phase, end-of-life issues, and resources. Extensively revised and rewritten, this edition contains new chapters on the latest approaches to treating ALS symptoms, the use of noninvasive ventilators, multidisciplinary team care, new guidelines being developed by the American Academy of Neurology for patients with ALS, the use of riluzole (Rilutek), and more. |
 |
Informed EMS Field Guide ALS Version 16th Edition by InforMed |
 |
Standard Motor Products ALS207 ABS Wheel Speed Sensor by Standard Motor Products Standard Motor Products ALS207 ABS Speed Sensor. Need to verify application? Go to http://www.standardbrand.com/web_app/catalog/smp_bgbulk.aspx for online images and application or simply click on the Standard logo at the bottom of this page |
 |
ERIC IS WINNING !!: Beating a Terminal Illness with Nutrition, Avoiding Toxins and Common Sense by Eric Edney (Author) What do you do when your medical doctor tells you that you have a terminal illness and to go home and die- there is no cure? The book explains Eric's reaction and successful fourteen-year survival. The purpose of this book is to provide information and |
 |
Suncast ALS17 Loft Shelf by Suncast Corporation For use with Suncast storage buildings. Shelf is coated with a durable powder coated finish. Capacity rated for 30 lb., evenly distributed. Shelf size: 50" W. x 17" D. x 12" H. Color: Taupe. |
|
Information Deutsch Als Fremdsprache - Info Daf by Iudicium Verlag |
| © 2010 BrightSurf.com |